HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda

Clinical Infectious Diseases

Volumn 49, Issue 5, 2009, Pages 780-786

  Sacktor, Ned ^a,g   Nakasujja, Noeline ^e   Skolasky, Richard L ^a   Rezapour, Mona ^b   Robertson, Kevin ^c   Musisi, Seggane ^e   Katabira, Elly ^e   Ronald, Allan ^f   Clifford, David B ^d   Laeyendecker, Oliver ^a,b   Quinn, Thomas C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAKERERE UNIVERSITY   (Uganda)

^f UNIVERSITY OF MANITOBA   (Canada)

^g JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN; GLYCOPROTEIN 41; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DATA ANALYSIS; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE INSERTION; GENE SEQUENCE; GENETIC ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSUPPRESSIVE TREATMENT; MALE; NEUROPSYCHOLOGICAL TEST; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; RISK ASSESSMENT; RNA EXTRACTION; UGANDA; VIRUS STRAIN;

ADULT; AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VARIATION; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MOLECULAR SEQUENCE DATA; PHYLOGENY; RNA, VIRAL; UGANDA;

EID: 70149091300     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605284     Document Type: Article

References (36)

1. Wong M, Robertson K, Nakasujja N, et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 2007; 68:350-355 (Pubitemid 46184210)
2. Liner KJ, Hall CD, Robertson KR. Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease. J Neurovirol 2007; 13:291-304. (Pubitemid 47400028)
3. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of Human Immunodeficiency Virus Type 1 (HIV-1) Subtype on Disease Progression in Persons from Rakai, Uganda, with Incident HIV-1 Infection. J Infect Dis 2008; 197:707-713
4. Kaleebu P, French N, Mahe C, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002; 185:1244-1250 (Pubitemid 34439131)
5. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843-852 (Pubitemid 43363943)
6. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195:1177-1180 (Pubitemid 46543449)
7. Sacktor N, Nakasujja N, Skolasky R, et al. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 2009; 72:165-170
8. SacktorNC,WongM,NakasujjaN,etal.TheInternationalHIVDementiaScale: anewrapidscreeningtestforHIVdementia.AIDS2005;19:1367-1374(Pubitemid41800672)
9. Karnofsky DA, Abelman WH, Craver LF, Burchenal J. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1:634-656
10. Maj M, Satz P, Janssen R, et al. WHO Neuropsychiatric AIDS Study, Cross-sectional Phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry 1994; 51:51-61.
11. Smith A. Symbol digit modalities test. Los Angeles: Western Psychological Service 1982.
12. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988; 158:1079-1083
13. Yang C, Dash BC, Simon F, et al. Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic pol and env primer pairs. J Infect Dis 2000; 181:1791-1795 (Pubitemid 30387779)
14. Yang C, Dash B, Hanna SL, et al. Predominance of HIV type 1 subtype G among commercial sex workers from Kinshasa, Democratic Republic of Congo. AIDS Res Hum Retroviruses 2001; 17:361-365
15. Hall TA. BioEdit: a user-friendly biological sequencealignment editorand analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999; 41:95-98
16. Felsentein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985; 39:783-791
17. CarrJK,SalminenMO,KochC,etal.Full- lengthsequenceandmosaicstructureofahumanimmunodeficiencyvirustype1isolatefro mThailand.JVirol1996;70:5935-5943(Pubitemid26266807)
18. Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73:152-160
19. Antinori A, Arendt. G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders (HAND). Neurology 2007; 69:1789-1799 (Pubitemid 350059308)
20. Kanki PJ, Hamel DJ, Sankale JL, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179: 68-73. (Pubitemid 29028340)
21. EshlemanSH,GuayLA,MwathaA,etal.Comparisonofmother-tochildtransmission, ratesinUgandanwomenwithsubtypeAversusDHIV-1whoreceivedsingle- dosenevirapineprophylaxis:HIVNetworkForPreventionTrials012. JAcquirImmuneDeficSyndr2005;39:593-597(Pubitemid41098476)
22. PeetersM,VincentR,PerretJL,etal. EvidencefordifferencesinMT2celltropismaccording-geneticsubtypesofHIV-1: syncytium-inducingvariantsseemrareamongsubtypeCHIV-1viruses. JAcquirImmuneDeficSyndrHumRetroviral1999;20:115-121(Pubitemid29063708)
23. Tscherning C, Alaeus A, Fredriksson R, et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998; 241:181-188 (Pubitemid 28384191)
24. Kaleebu P, Nankya IL, Yirrell DL, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007; 45:28-33. (Pubitemid 46684440)
25. Li W, Huang Y, Reid R, et al. NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci 2008; 28:12190-12198
26. De Jong JJ, De Ronde A, Keulen W, et al. Minimal requirements forthe human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992; 66:6777-6780
27. Zhong P, Peeters M, Janssens W, et al. Correlation between genetic and biological properties of biologically cloned HIV type 1 viruses representing subtypes A, B, and D. AIDS Res Hum Retroviruses 1995; 11: 239-248
28. Dunfee RL, Thomas ER, Gorry PR, et al. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A 2006; 103:15160-15165
29. Pillai SK, Pond SL, Liu. Y, et al. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain 2006; 129:1872-1883 (Pubitemid 43999418)
30. deWolfF,HogervorstE,GoudsmitJ,etal.Syncytium-inducingandnon-syncytium- inducingcapacityofhumanimmunodeficiencyvirustype1subtypesotherthanB: phenotypicandgenotypiccharacteristics. WHONetworkforHIVIsolationandCharacterization.AIDSResHumRetroviruses1994;10: 1387-1400(Pubitemid24382189)
31. Johnston JB, Jiang Y, van Marle G, et al. Lentivirus infection in the brain induces matrix metalloproteinase expression: role of envelope diversity. J Virol 2000; 74:7211-7220 (Pubitemid 30613068)
32. MankowskiJL,FlahertyMT,SpelmanJP,etal. Pathogenesisofsimianimmunodeficiencyvirusencephalitis: viraldeterminantsofneurovirulence.JVirol1997;71:6055-6060(Pubitemid27304945)
33. Ritola K, Robertson K, Fiscus SA, et al. Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol 2005; 79:10830-10834
34. Liesch GR, DeStefano JJ. Analysis of mutations made during active synthesis or extension of mismatched substrates further define the mechanism of HIV-RT mutagenesis. Biochemistry 2003; 42:5925-5936
35. Simon V, Ho DD. HIV-1 dynamics in vivo: implications for therapy. Nat Rev Microbiol 2003; 1:181-190
36. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20:W13-W23.